Antibiotic resistance is one of the most urgent public health challenges of our time — and the research community is fighting back. During April 2026, , Fedora Pharmaceuticals presented a comprehensive body of preclinical data on its lead candidate, FPI-2119, at ESCMID Global 2026 in Munich, Germany (April 17–21). With eight poster presentations, the breadth of evidence on display reflects the enormous potential of FPI-2119 to become a transformative new tool in the fight aga